Study of How Blood and Nasal Antibodies Fight COVID-19 and Monkeypox Over Time After Vaccination or Treatment

What this Trial Is About

This research aims to measure and describe how the bodys antibody response changes over time after receiving vaccines or monoclonal antibody treatments for COVID-19 and Monkeypox. It focuses on people who may be at higher risk due to weakened immune systems or other health conditions. The study evaluates the strength of neutralizing antibodies in the blood and nasal passages as a sign of protection against these infections. Participants receive standard vaccines or monoclonal antibody treatments for SARS-CoV-2 andor Monkeypox as part of their usual care. The study itself does not provide these treatments but collects blood and optional nasal samples at each visit to analyze antibody activity. Samples are tested using validated methods to assess neutralizing power against both viruses. Each participant is followed for up to 60 months, during which blood and nasal samples are collected multiple times to track changes in antibody levels. Researchers will study the evolution of serum and mucosal antibody responses over this period. The study monitors how long protection lasts and collects detailed laboratory results related to immune response while participants continue their routine health care.

Neutralizing Power of Serum Antibodies - 2